BSW Wealth Partners Buys Shares of 684 Regeneron Pharmaceuticals, Inc. $REGN

BSW Wealth Partners purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 684 shares of the biopharmaceutical company’s stock, valued at approximately $385,000.

A number of other hedge funds also recently modified their holdings of the business. Bar Harbor Wealth Management increased its stake in Regeneron Pharmaceuticals by 36.8% during the 3rd quarter. Bar Harbor Wealth Management now owns 12,280 shares of the biopharmaceutical company’s stock worth $6,905,000 after purchasing an additional 3,304 shares in the last quarter. Hunter Perkins Capital Management LLC increased its position in shares of Regeneron Pharmaceuticals by 37.1% during the third quarter. Hunter Perkins Capital Management LLC now owns 11,616 shares of the biopharmaceutical company’s stock worth $6,531,000 after acquiring an additional 3,143 shares in the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the third quarter. Harbor Capital Advisors Inc. now owns 1,583 shares of the biopharmaceutical company’s stock worth $890,000 after acquiring an additional 46 shares during the period. Norden Group LLC lifted its position in Regeneron Pharmaceuticals by 103.7% in the 3rd quarter. Norden Group LLC now owns 1,106 shares of the biopharmaceutical company’s stock valued at $622,000 after acquiring an additional 563 shares in the last quarter. Finally, Tritonpoint Wealth LLC boosted its stake in Regeneron Pharmaceuticals by 11.3% in the 3rd quarter. Tritonpoint Wealth LLC now owns 2,767 shares of the biopharmaceutical company’s stock worth $1,556,000 after purchasing an additional 281 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on REGN. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Cantor Fitzgerald boosted their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Guggenheim lifted their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Finally, Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $779.45.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $784.97 on Friday. The company has a fifty day moving average price of $703.50 and a two-hundred day moving average price of $609.65. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $792.77. The stock has a market cap of $82.50 billion, a P/E ratio of 18.80, a P/E/G ratio of 2.25 and a beta of 0.37. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the previous year, the firm earned $12.46 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.